{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:01:28Z","timestamp":1790874088431,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.018","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:30:26Z","timestamp":1785367826000},"page":"661-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5324-1216","authenticated-orcid":false,"given":"Cheryl H.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-9853","authenticated-orcid":false,"given":"Allison O.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-3336","authenticated-orcid":false,"given":"Nia M.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-4238","authenticated-orcid":false,"given":"Susan C.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5410-8146","authenticated-orcid":false,"given":"Jesse D.","family":"Troy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca P.","family":"Bystrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2026.07.018_bib0001","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.018_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000548334","article-title":"Real world experience of azacitidine + venetoclax in acute myeloid leukemia rigorously following management guidelines from clinical trial","author":"Sedaki","year":"2025","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.07.018_bib0003","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"2","key":"10.1016\/j.clml.2026.07.018_bib0004","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.27180","article-title":"Venetoclax duration (14 vs. 21 vs. 28\u2009days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival","volume":"99","author":"Karrar","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.07.018_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients","volume":"15","author":"Willekens","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.07.018_bib0006","doi-asserted-by":"crossref","first-page":"108204","DOI":"10.1016\/j.leukres.2026.108204","article-title":"A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy","volume":"164","author":"Ambinder","year":"2026","journal-title":"Leuk Res"},{"issue":"18","key":"10.1016\/j.clml.2026.07.018_bib0007","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood.2025029691","article-title":"A clinical guide to TP53 mutations in myeloid neoplasms","volume":"146","author":"Urrutia","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.07.018_bib0008","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2026.07.018_bib0009","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2026.07.018_bib0010","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.07.018_bib0011","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.clml.2026.07.018_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082248","article-title":"What\u2019s next after hypomethylating agents failure in myeloid neoplasms? A rational approach","volume":"15","author":"Awada","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2026.07.018_bib0013","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2026.07.018_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/genes11080845","article-title":"AML with myelodysplasia-related changes: development, challenges, and treatment advances","volume":"11","author":"Koenig","year":"2020","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.clml.2026.07.018_bib0015","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/cncr.35214","article-title":"Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt","volume":"130","author":"Sedeta","year":"2024","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2026.07.018_bib0016","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1038\/s41375-025-02730-3","article-title":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model","volume":"39","author":"Venditti","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.07.018_bib0017","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ph17040484","article-title":"Venetoclax-related neutropenia in leukemic patients: a comprehensive review of the underlying causes, risk factors, and management","volume":"17","author":"Di Pasqua","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.clml.2026.07.018_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:16:59Z","timestamp":1790871419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002430"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}